Related Experiment Videos
Clinical experiences in an open and a double-blind trial
Acta Psychiatrica Belgica
|January 1, 1978
Summary
Bromperidol demonstrated significant efficacy in treating psychotic syndromes, particularly schizophrenia. This antipsychotic showed promising results with minimal side effects, suggesting potential superiority over haloperidol.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Antipsychotic medications are crucial for managing psychotic disorders.
- Bromperidol is a novel antipsychotic agent evaluated for its therapeutic potential.
Purpose of the Study:
- To assess the efficacy and tolerability of bromperidol in patients with psychotic syndromes.
- To compare bromperidol with haloperidol, a standard antipsychotic, in a double-blind study.
Main Methods:
- An open-label study followed by a double-blind, placebo-controlled trial involving 60 patients.
- Patients received bromperidol or haloperidol for four weeks, with doses adjusted as needed.
Main Results:
- Bromperidol showed very good to good therapeutic results in 18 out of 19 patients in the open study.
- Both bromperidol and haloperidol were highly effective for schizophrenia, with bromperidol possibly having a faster onset of action.
- Mild to moderate extrapyramidal symptoms were noted, but no significant toxic effects or other side effects were observed.
Conclusions:
- Bromperidol is an effective and well-tolerated antipsychotic for psychotic syndromes, especially schizophrenia.
- Bromperidol may offer advantages over haloperidol, warranting further investigation.